V8 Peptides — Engineered Performance
Research Library
Melanotan II to PT-141: History of a Peptide Lineage
Melanotan IIHistory

Melanotan II to PT-141: History of a Peptide Lineage

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

How is PT-141 related to Melanotan II? Both are cyclic heptapeptides built on the same core, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys], which descends from α-melanocyte-stimulating hormone via the potent analog NDP-MSH (1980) and the cyclic lactam analogs reported in 1989. They differ only at the C-terminus: Melanotan II ends in an amide (-NH2) and PT-141, also called bremelanotide, in a free acid (-OH). The V8 MT-2 vial is 10 mg (C50H69N15O9), the PT-141 vial is 10 mg (C50H68N14O10), both ≥98% HPLC. For laboratory research use only; not for human consumption.

The names Melanotan II and PT-141 are often presented as if they were unrelated products. Chemically they are siblings, and the relationship is easy to see once the lineage is laid out from the natural hormone down. This article follows that lineage in order: the native peptide, the first potent analog, the cyclization idea, and the two closely related heptapeptides sold today as research materials. The focus is chemistry and published history. The compounds are supplied for laboratory research use only, and nothing here is guidance for any person.

Starting point: α-MSH and the melanocortin system

α-Melanocyte-stimulating hormone is a 13-residue peptide cleaved from the precursor proopiomelanocortin. It acts on a family of five G protein-coupled melanocortin receptors, MC1R to MC5R, which are distributed differently across skin, brain, adrenal and other tissues. Cone reviewed the physiological functions of this system (Cone, 2006). For a chemist, α-MSH has two limitations as a laboratory ligand: it is rapidly broken down by peptidases, and it is conformationally flexible, so it binds several receptor subtypes with modest selectivity. Most of the history that follows is an attempt to fix one or both of those problems.

Step one: NDP-MSH (1980)

Sawyer and colleagues reported 4-norleucine, 7-D-phenylalanine-α-MSH, usually abbreviated NDP-MSH or melanotan-I in its related forms, as a highly potent α-melanotropin with ultralong biological activity (Sawyer and colleagues, 1980). Two substitutions did the work. Replacing methionine at position 4 with norleucine removes an oxidation-prone sulfur while keeping a similar side chain length, and replacing L-phenylalanine at position 7 with its D-isomer is consistent with greater resistance to proteolysis and a stabilized turn. These are standard peptide-design moves, applied here to a natural hormone sequence, and the potency gain was large enough to make the compound a reference agonist in the field. The related linear analog is available as MT-1; see what is Melanotan I for that branch of the family.

Step two: cyclization by lactam bridge (1989)

A linear peptide of this length can adopt many shapes. Locking the active region into a ring is a way to bias it toward the shape the receptor recognizes and to protect it from exopeptidases. Al-Obeidi and colleagues described potent and prolonged-acting cyclic lactam analogs of α-melanotropin, with a design based on molecular dynamics (Al-Obeidi and colleagues, 1989). The ring is formed by an amide (lactam) bond between the side chains of aspartic acid and lysine. A lactam is not reduced by thiols and does not undergo disulfide exchange, which makes it the more robust choice for a reagent that will be handled in many buffers. The product of this approach, a seven-residue ring built around the His-Phe-Arg-Trp stretch that melanocortin receptors recognize, is Melanotan II.

The two heptapeptides side by side

The sequences below come from the V8 product pages for MT-2 and PT-141.

AttributeMT-2 (Melanotan II)PT-141 (bremelanotide)
Class on product pageCyclic heptapeptide, α-MSH analogCyclic heptapeptide, melanocortin agonist
SequenceAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
C-terminusAmideFree carboxylic acid
Molecular formulaC50H69N15O9C50H68N14O10
Vial size10 mg10 mg
Purity≥98% (HPLC)≥98% (HPLC)
Supplied formLyophilized powderLyophilized powder
Storage2–8 °C; −20 °C long-term; protect from heat, moisture and light2–8 °C; −20 °C long-term; protect from heat, moisture and light

Subtract one formula from the other and the difference is an amide nitrogen and one hydrogen on one side, one oxygen on the other: the C-terminal -NH2 of Melanotan II becomes -OH in PT-141. Everything else, including the ring, the D-phenylalanine and the N-terminal acetyl-norleucine, is shared. Hadley and Dorr traced the milestones of this family, including the relation of the later compounds to the Melanotan lineage (Hadley and Dorr, 2006); their review is the best single starting point for the commercial and clinical side of the story, which this page does not cover.

Why a single end-group change deserves attention

A C-terminal amide and a free acid differ in charge at neutral pH: the amide is neutral, the acid is negatively charged. In a peptide whose core carries a positive arginine and a basic lysine side chain, that change shifts the net charge of the molecule, and it can alter solubility, chromatographic retention, adsorption to surfaces and receptor selectivity. Experimenters should therefore avoid assuming that behavior measured with one compound applies to the other. A comparison of how the two have been described in research is the topic of PT-141 vs Melanotan II, and a rodent behavioral study that used a melanocortin receptor agonist from this family is that of Pfaus and colleagues (2004), cited for the existence of such work only.

Property that can differReasonPractical check
HPLC retention timeDifferent end-group polarity and chargeRun both against their own reference, not each other's
Solubility and adsorptionDifferent net chargeUse low-binding tubes for dilute solutions of either
Receptor subtype profileTerminal group can contact the binding pocketTest each compound in the receptor panel; do not assume equivalence
Mass in identity checksOne mass unit apart (amide vs acid: 0.98 Da)Use a method with enough resolution to separate them

The last row has a practical consequence: the monoisotopic masses of an amide and its acid counterpart differ by only about 0.98 Da. A low-resolution mass check can confuse them, and a partly deamidated amide sample would contain a small acid-form component. This is one reason identity data for melanocortin analogs should be read with the exact formula in front of you. How to read such data is covered in how to read a COA, with compound-specific notes at Melanotan II purity testing and PT-141 purity testing.

Reading the names correctly

Nomenclature in this family is a common source of confusion in notebooks and in purchase records. NDP-MSH is the linear 1980 analog; Melanotan I is the name used for that line of linear analogs; Melanotan II or MT-II is the cyclic lactam heptapeptide with the C-terminal amide; PT-141 and bremelanotide refer to the cyclic heptapeptide with the free C-terminal acid. When a paper reports a result with "a melanocortin agonist", check the methods for the exact compound and the exact end group before comparing it with another paper, because the three structures are close but not interchangeable. The same care applies to your own records: write the full name and the formula on the tube label, not an abbreviation alone.

Dated source table

YearSourceContribution to the lineage
1980Sawyer and colleagues, Proc Natl Acad SciNDP-MSH, a highly potent, long-acting α-melanotropin analog
1989Al-Obeidi and colleagues, J Med ChemCyclic lactam analogs, prolonged action, design from molecular dynamics
2004Pfaus and colleagues, Proc Natl Acad SciRodent behavioral study using a melanocortin receptor agonist
2006Cone, Endocr RevReview of the physiological functions of the melanocortin system
2006Hadley and Dorr, PeptidesReview of historical milestones, studies and commercialization of melanocortin peptides

Bench notes for the two vials

  1. Label by the exact compound. Both are ten-milligram, ≥98% HPLC vials with the same storage line, so keep records unambiguous.
  2. Let the vial warm, add diluent against the wall, swirl. General steps are in how to reconstitute a lyophilized peptide.
  3. Calculate, do not copy. Concentration is c = m / V and moles are n = m / M; the calculator handles conversion.
  4. Protect from light. The sequences contain tryptophan, which is photosensitive.
  5. Verify the lot. Compare the lot number with the entry in the COA library where a certificate has been published.

Limits of this account

The sources establish the chemistry of the analogs and the order of their discovery. They do not establish a validated shelf life for reconstituted research-grade material, and this page makes no claim about outcomes in any living system. The broader reference for the compound is the Melanotan II research overview, and a plain-language explainer for the other member of the pair is what is PT-141. Sourcing considerations are discussed in where to buy Melanotan II. All material is listed in the research catalog for laboratory research use only.

Related reading

Frequently asked questions

How is PT-141 related to Melanotan II?

They share the same cyclic core, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]. Melanotan II ends in a C-terminal amide and PT-141 in a free acid.

What is NDP-MSH?

4-Norleucine, 7-D-phenylalanine-α-MSH, reported by Sawyer and colleagues in 1980 as a highly potent α-melanotropin with ultralong biological activity. It is an ancestor of the cyclic analogs.

What does the lactam bridge do?

It joins the side chains of aspartic acid and lysine to close a ring. That constrains the peptide and, unlike a disulfide, is not reduced by thiols or subject to disulfide exchange.

What is the formula difference between MT-2 and PT-141?

MT-2 is C50H69N15O9 and PT-141 is C50H68N14O10. The difference corresponds to replacing the C-terminal amide with a carboxylic acid.

Why can mass spectrometry confuse an amide with its acid?

The monoisotopic masses differ by only about 0.98 Da, so a low-resolution method can fail to separate them. Read identity data against the exact formula.

Do the two vials share a storage line?

Yes. Both product pages state 2–8 °C, −20 °C for long-term holding, and protection from heat, moisture and light.

What vial size is each compound sold in?

The product pages list 10 mg lyophilized powder for both MT-2 and PT-141, each with purity ≥98% by HPLC.

Which papers describe the history of melanocortin peptides?

Sawyer and colleagues (1980), Al-Obeidi and colleagues (1989), and the reviews by Cone (2006) and Hadley and Dorr (2006) are the key sources used on this page.

How do I calculate the stock concentration?

Divide vial mass by diluent volume (c = m / V). Use the reconstitution calculator for unit conversions and record lot, diluent and date.

Is a validated shelf life published for reconstituted MT-2 or PT-141?

Not in the sources used here. Keep solutions cold, limit time in solution, freeze single-use portions for longer holding and re-verify by HPLC when exact concentration matters.

Related reading: Melanotan II (MT-2): A Laboratory Handbook.

References

  1. Sawyer TK, Sanfilippo PJ, Hruby VJ, et al. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci USA. 1980;77(10):5754-5758. doi:10.1073/pnas.77.10.5754
  2. Al-Obeidi F, Castrucci AM, Hadley ME, Hruby VJ. Potent and prolonged-acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. J Med Chem. 1989;32(12):2555-2561. doi:10.1021/jm00132a010
  3. Pfaus J, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci USA. 2004;101(27):10201-10204. doi:10.1073/pnas.0400491101
  4. Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev. 2006;27(7):736-749. doi:10.1210/er.2006-0034
  5. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. doi:10.1016/j.peptides.2005.01.029

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.